CDK9-IN-2

• CAS Number:

  1263369-28-3

• UNSPSC Description:

  CDK9-IN-2 is a special cyclin-dependent kinase 9 (CDK9) inhibitor, extracted from patent WO/2012131594A1, compound CDKI(8), has an IC50 of 5 nM and 7 nM in H929 multiple myeloma(MM) cell line (72 hours) and A2058 skin cell line (72 hours), respectively.

• Target Antigen:

  CDK

• Type:

  Reference compound

• Related Pathways:

  Cell Cycle/DNA Damage

• Applications:

  COVID-19-anti-virus

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/cdk9-in-2.html

• Solubility:

  DMSO : 50 mg/mL (ultrasonic)

• Smiles:

  ClC1=CN=C(N[C@@H]2CC[C@@H](N)CC2)C=C1C3=NC(NCC4=CC(F)=CC=C4)=CC=C3

• Molecular Weight:

  425.93

• References & Citations:

  [1]Michel Faure, et al. Pharmacodynamic markers associated with cyclin-dependent kinase inhibitors. From PCT Int. Appl. (2012), WO 2012131594A1

• Shipping Conditions:

  Room Temperature

• Clinical Information:

  No Development Reported